摘要:
It is intended to provide novel amine compounds which are efficacious against diseases such as infection with HIV virus, rheumatism and cancer metastasis. Namely, amine compounds represented by the following general formula (1): In a typical case, A1 and A2 represent each an optionally substituted monocyclic or polycyclic aromatic heterocycle; W represents cyclic C3-10 alkylene, an optionally substituted monocyclic or polycyclic aromatic heterocycle, a monocyclic or polycyclic aromatic ring or a partly saturated polycyclic aromatic ring; X represents O, CH2, C(═O) or NR11; and D is a group represented by the following general formula (4) or (6). In the formula (6), Q represents a single bond, S, O or NR12; and Y is a group represented by the following general formula (7). z represents an optionally substituted monocyclic or polycyclic aromatic ring. In the formula (6), B represents NR25R26. In the above formulae, R1 to R26 each represents hydrogen, alkyl, alkenyl or alkynyl.
摘要:
Novel amine compounds which are efficacious against diseases such as infection with HIV virus, rheumatism, and cancer metastasis include compounds represented by the following general formula (1), a pharmacologically acceptable salt thereof, or a prodrug thereof: wherein each of n1, n2, and n3 is an integer of 1; each of R1, R2, R3, R4, R5, and R6 is independently a hydrogen atom; A1 is imidazole; A2 is imidazole or imidazole substituted with an alkyl group; W is a phenyl group or naphthyl group; X is CH2; D is a group represented by -Q-Y—B, wherein Q is NR12 and R12 is a hydrogen atom or an alkyl group; Y is (CH2)m3 and m3 is an integer of 2 to 4; and B is N(R25R26), wherein each of R25 and R26 are independently a hydrogen atom, a C1–C6 alkyl group or a C3–C6 cycloalkyl group.
摘要:
It is intended to provide novel amine compounds which are efficacious against diseases such as infection with HIV virus, rheumatism and cancer metastasis. Namely, amine compounds represented by the following general formula (1): In a typical case, A1 and A2 represent each an optionally substituted monocyclic or polycyclic aromatic heterocycle; W represents cyclic C3-10 alkylene, an optionally substituted monocyclic or polycyclic aromatic heterocycle, a monocyclic or polycyclic aromatic ring or a partly saturated polycyclic aromatic ring; X represents O, CH2, C(═O) or NR11; and D is a group represented by the following general formula (4) or (6). In the formula (6), Q represents a single bond, S, O or NR12; and Y is a group represented by the following general formula (7). z represents an optionally substituted monocyclic or polycyclic aromatic ring. In the formula (6), B represents NR25R26. In the above formulae, R1 to R26 each represents hydrogen, alkyl, alkenyl or alkynyl.
摘要:
It is intended to provide novel amine compounds which are efficacious against diseases such as infection with HIV virus, rheumatism and cancer metastasis. Namely, amine compounds represented by the following general formula (1): In a typical case, A1 and A2 represent each an optionally substituted monocyclic or polycyclic aromatic heterocycle; W represents cyclic C3-10 alkylene, an optionally substituted monocyclic or polycyclic aromatic heterocycle, a monocyclic or polycyclic aromatic ring or a partly saturated polycyclic aromatic ring; X represents O, CH2, C(═O) or NR11; and D is a group represented by the following general formula (4) or (6). In the formula (6), Q represents a single bond, S, O or NR12; and Y is a group represented by the following general formula (7). z represents an optionally substituted monocyclic or polycyclic aromatic ring. In the formula (6), B represents NR25R26. In the above formulae, R1 to R26 each represents hydrogen, alkyl, alkenyl or alkynyl.
摘要:
The present invention provides novel compounds having antiviral activities and antiviral drugs containing the compounds as the active ingredient. The compounds are shown by the following general formula (1), wherein typically A1 and A2 are each guanidine or a group of the general formula (ia); A3 is a mono- or poly-cyclic heteroaromatic ring containing 1 or 2 heteroatoms; B1 is a single bond or alkylene group; R1 is hydrogen or alkyl group; W is an alkylene having 2-3 carbons, a cycloalkylene having 5-10 carbons, aromatic ring having 6-10 carbons, or a heteroaromatic ring having 5-10 carbons; y is C(═O)—; x is —C(═O)—NH—; n1 is an integer of 1-2; n2 is an integer of 2-3; D is a substituent selected from among various groups
摘要翻译:本发明提供具有抗病毒活性的新化合物和含有该化合物作为活性成分的抗病毒药物。 所述化合物由以下通式(1)表示,其中通常A 1和A 2各自为胍或通式(ia)的基团。 A 3是含有1或2个杂原子的单环或多环杂芳环; B 1是单键或亚烷基; R 1是氢或烷基; W是具有2-3个碳的亚烷基,具有5-10个碳的亚环烷基,具有6-10个碳的芳族环,或具有5-10个碳的杂芳族环; y为C(-O) - ; x是-C(-O)-NH-; n 1是1-2的整数; n≥2是2-3的整数; D是选自不同组的取代基
摘要:
A human ADAMTS-1 protein, a gene encoding the same, a pharmaceutical composition containing the protein as an active ingredient, and a method for immunologically analyzing the human ADAMTS-1 protein are disclosed. The protein can decrease the number of leukocytes and platelets, and at the same time, increase the number of erythrocytes.
摘要:
Novel proteins, novel genes encoding the same, plasmids respectively comprising these genes, transformants respectively comprising these plasmids, antibodies or fragments thereof against the above novel proteins, methods of detecting a bacterial infection, and novel polynucleotides are disclosed. The novel proteins are activated human macrophage-specific proteins.
摘要:
The present invention provides a diagnostic method for cancer, a screening method for a cancer growth inhibitor, and a pharmaceutical composition used in cancer therapy using a Nox1 gene associated with a mutant Ras oncogene. More specifically, the present invention relates to: a composition for producing an antibody, comprising a polypeptide coded for a Nox1 gene, a homologue thereof, and their peptide fragments; an antibody against the polypeptide coded for a Nox1 gene; and a method for detecting the antibody or Nox1-expressing mRNA.
摘要:
There are provided a polypeptide specific to liver cancer, a polynucleotide coding for the polypeptide, and an RNA molecule suppressing the expression of the polypeptide. The present invention is particularly intended for a polypeptide comprising the amino acid sequence of SEQ ID NO: 1; a polypeptide having at least 80% homology to the amino acid sequence of SEQ ID NO: 1 and having immunogenicity inducing the production of an antibody against the polypeptide comprising the amino acid sequence of SEQ ID NO: 1; nucleotide fragments thereof; polynucleotides coding for the polypeptides and fragments thereof; and an RNA molecule having a partial sequence corresponding to mRNA coding for the polypeptide comprising the amino acid sequence of SEQ ID NO: 1.
摘要翻译:提供了对肝癌特异性的多肽,编码多肽的多核苷酸以及抑制多肽表达的RNA分子。 本发明特别用于包含SEQ ID NO:1的氨基酸序列的多肽; 与SEQ ID NO:1的氨基酸序列具有至少80%同源性且具有诱导针对包含SEQ ID NO:1的氨基酸序列的多肽的抗体产生的免疫原性的多肽; 其核苷酸片段; 编码多肽及其片段的多核苷酸; 以及具有对应于编码包含SEQ ID NO:1的氨基酸序列的多肽的mRNA的部分序列的RNA分子。
摘要:
Novel proteins, novel genes encoding the same, plasmids respectively comprising these genes, transformants respectively comprising these plasmids, antibodies or fragments thereof against the above novel proteins, methods of detecting a bacterial infection, and novel polynucleotides are disclosed. The novel proteins are activated human macrophage-specific proteins.